Hemangioblasts for the Treatment of Vascular Diseases
ACT’s hemangioblast (HG) program for the treatment of blood and cardiovascular diseases is currently in preclinical development.
Hemangioblasts are newly-characterized stem cells capable of differentiating into both hematopoietic (blood cell-forming) and angiogenic (blood vessel endothelium-forming) cells. The latter comprise the single layer of tissue that lines the interior of the entire circulatory system, from the heart to the smallest capillary. Blood vessel endothelial cells are involved in control of blood pressure by constricting and dilation of blood vessels, clotting of blood, formation of new blood vessels and inflammation and swelling.
These bipotential progenitor cells can be efficiently and reproducibly generated from h